CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter's five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in incidence and prevalence of target conditions
3.5.1.2.Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
3.5.1.3.Surge in adoption of SPECT and PET scans
3.5.1.4.Developments in imaging technologies using radiopharmaceuticals

3.5.2.Restraint

3.5.2.1.Supply volatility, logistical challenges and stringent regulatory policies
3.5.2.2.Short half life of radiopharmaceuticals
3.5.2.3.Competition from conventional alternative diagnostic procedures

3.5.3.Opportunities

3.5.3.1.Use of radiopharmaceuticals in neurological applications

3.5.4.Impact analysis

3.6.COVID-19 Impact Analysis on Asia-Pacific nuclear medicines Market

CHAPTER 4:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Diagnostics

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast

4.3.Therapeutics

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast

4.4.Biochemistry Research

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast

CHAPTER 5:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY MODALITY

5.1.Overview

5.1.1.Market size and forecast

5.2.SPECT

5.2.1.Market size and forecast

5.3.PET

5.3.1.Market size and forecast

5.4.Beta emitters'

5.4.1.Market size and forecast

5.5.Alpha emitters

5.5.1.Market size and forecast

5.6.Brachytherapy

5.6.1.Market size and forecast

5.7.Others

5.7.1.Market size and forecast

CHAPTER 6:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY APPLICATION

6.1.Overview

6.1.1.Key market trends and opportunities
6.1.2.Market size and forecast

6.2.Oncology

6.2.1.Market size and forecast

6.3.Cardiology

6.3.1.Market size and forecast

6.4.Thyroid

6.4.1.Market size and forecast

6.5.Neurology

6.5.1.Market size and forecast

6.6.Others

6.6.1.Market size and forecast

CHAPTER 7:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY END USER

7.1.Overview

7.1.1.Market size and forecast

7.2.Hospitals and Diagnostic Centers

7.2.1.Market size and forecast

7.3.Research Institutes

7.3.1.Market size and forecast

CHAPTER 8:ASIA-PACIFIC NUCLEAR MEDICINE MARKET, BY REGION

8.1.Overview
8.2.Asia-Pacific

8.2.1.Key market trends, growth factors, and opportunities
8.2.2.Market size and forecast, by country

8.2.2.1.Japan

8.2.2.1.1.Asia-Pacific nuclear medicine market, for Japan, by type
8.2.2.1.2.Asia-Pacific nuclear medicine market, for Japan, by modality
8.2.2.1.3.Asia-Pacific nuclear medicine market, for Japan, by application
8.2.2.1.4.Asia-Pacific nuclear medicine market, for Japan, by end user

8.2.2.2.China

8.2.2.2.1.Asia-Pacific nuclear medicine market, for China, by type
8.2.2.2.2.Asia-Pacific nuclear medicine market, for China, by modality
8.2.2.2.3.Asia-Pacific nuclear medicine market, for China, by application
8.2.2.2.4.Asia-Pacific nuclear medicine market, for China, by end user

8.2.2.3.India

8.2.2.3.1.Asia-Pacific nuclear medicine market, for India, by type
8.2.2.3.2.Asia-Pacific nuclear medicine market, for India, by modality
8.2.2.3.3.Asia-Pacific nuclear medicine market, for India, by application
8.2.2.3.4.Asia-Pacific nuclear medicine market, for India, by end user

8.2.2.4.South Korea

8.2.2.4.1.Asia-Pacific nuclear medicine market, for South Korea, by type
8.2.2.4.2.Asia-Pacific nuclear medicine market, for South Korea, by modality
8.2.2.4.3.Asia-Pacific nuclear medicine market, for South Korea, by application
8.2.2.4.4.Asia-Pacific nuclear medicine market, for South Korea, by end user

8.2.2.5.Australia

8.2.2.5.1.Asia-Pacific nuclear medicine market, for Australia, by type
8.2.2.5.2.Asia-Pacific nuclear medicine market, for Australia, by modality
8.2.2.5.3.Asia-Pacific nuclear medicine market, for Australia, by application
8.2.2.5.4.Asia-Pacific nuclear medicine market, for Australia, by end user

8.2.2.6.Rest of Asia-Pacific

8.2.2.6.1.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by type
8.2.2.6.2.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by modality
8.2.2.6.3.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by application
8.2.2.6.4.Asia-Pacific nuclear medicine market, for Rest of Asia-Pacific, by end user

8.2.3.Asia-Pacific market size and forecast, by type
8.2.4.Asia-Pacific market size and forecast, by modality
8.2.5.Asia-Pacific market size and forecast, by application
8.2.6.Asia-Pacific market size and forecast, by end user

CHAPTER 9:COMPANY PROFILES

9.1.Bracco S.P.A. (Bracco Imaging S.P.A.)

9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Key strategic moves and developments

9.2.Bwx Technologies, Inc. (Nordion, Inc.)

9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments

9.3.Cardinal Health, Inc.

9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance

9.4.Danaher Corporation (GE Healthcare)

9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments

9.5.FUJIFILM Toyama Chemical Co., Ltd. (FUJIFILM Holdings Corporation)

9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance

9.6.Ion Beam Applications (Ion Beam Applications, SA)

9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.6.6.Key strategic moves and developments

9.7.Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)

9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance

9.8.Novartis AG (Advanced Accelerator Applications S.A.)

9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance

9.9.Otsuka Holdings Co., Ltd. (ABX advanced biochemical compounds GmbH)

9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance

9.10.Siemens Healthcare GmbH

9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance